Natural Compound

Probiotic

Various (Lactobacillus, Bifidobacterium, Saccharomyces, etc.)

Evidence TierBWADA NOT PROHIBITED

tuneTypical Dose

5–50 billion CFU per day

watchEffect Window

GI outcomes often begin in 1-4 weeks. Immune-support outcomes generally require sustained daily use.

check_circleCompliance

WADA NOT PROHIBITED

Overview

Clinical Summary

Probiotics are live microorganisms that can support antibiotic-associated diarrhea prevention and selected IBS or urinary-health outcomes, but benefits are strongly strain- and protocol-specific.

The clearest class-level evidence supports lower antibiotic-associated diarrhea risk when selected probiotics are taken alongside antibiotics. IBS symptom improvement is also possible, but pooled evidence remains inconsistent and depends on the exact strain, dose, and patient subtype. Selected lactobacillus protocols also have narrower evidence for recurrent urinary or vaginal-health support in women. Research on mood, eczema, respiratory infections, and immune outcomes is mixed and population-specific, and many commercial products do not match clinically studied strains.

Probiotics support gut ecology via competitive exclusion of pathogens, short-chain fatty-acid production, barrier support, and immune modulation through gut-associated lymphoid tissue signaling.

Outcomes

What This Is Expected To Influence

Primary Outcomes

  • Lower incidence of antibiotic-associated diarrhea when dosed during antibiotic exposure.
  • Possible improvement in IBS symptoms, especially bloating and bowel-pattern disruption, in strain-matched protocols.

Secondary Outcomes

  • Narrow recurrent-UTI prevention support in premenopausal women, especially with vaginal lactobacillus protocols.
  • Reduced frequency and severity of upper respiratory tract infections in some adult cohorts, though not consistently across all populations.
  • Early but mixed evidence for mood and anxiety support through gut-brain-axis signaling.

Safety

Contraindications and Interactions

Contraindications

  • Severe immunocompromise
  • Central venous catheter (fungemia risk with S. boulardii)
  • Short bowel syndrome
  • Prematurity

Side effects

  • Gas
  • Bloating
  • Mild GI discomfort (typically transient)

Interactions

  • Antibiotics kill probiotic organisms. Separate by >=2 hours
  • Immunosuppressants may increase infection risk from live organisms
  • Antifungals may inactivate yeast-based strains (e.g., S. boulardii)

Avoid if

  • Severely immunocompromised
  • Critically ill or ICU-admitted
  • Indwelling central venous catheter
  • Active malignancy without clinician clearance

Evidence

Study-level References

probiotic-SRC-001Systematic review and meta-analysis of randomized controlled trials
Sourceopen_in_new

Hempel S, Newberry SJ, Maher AR, et al. Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis. JAMA. 2012;307(18):1959-1969. doi:10.1001/jama.2012.3507. PMID:22570464.

Population: Adults and children receiving antibiotics across 63 prevention trials included in the pooled AAD analysis.

Dose protocol: Lactobacillus, Bifidobacterium, Saccharomyces, Streptococcus, Enterococcus, and Bacillus probiotic preparations used for prevention or treatment of antibiotic-associated diarrhea.

Key findings: Across 63 randomized prevention trials, probiotics were associated with lower antibiotic-associated diarrhea risk (RR 0.58, 95% CI 0.50-0.68), but strain reporting and trial heterogeneity were substantial.

Notes: Use as the legacy high-weight pooled AAD anchor, but not as proof that all probiotic products are interchangeable.

Paper content

This large JAMA meta-analysis remains one of the main pooled anchors for probiotic prevention of antibiotic-associated diarrhea. Across 63 randomized prevention trials involving 11,811 participants, probiotics were associated with lower AAD risk (RR 0.58, 95% CI 0.50-0.68), with an absolute risk reduction of 7% and an estimated number needed to treat of 13. The signal remained statistically robust across many subgroup analyses, but the authors emphasized substantial heterogeneity and poor strain documentation across trials. That makes the review useful for confirming a real class-level prevention signal while also reinforcing that clinicians cannot assume every commercial probiotic product will perform the same way.

probiotic-SRC-002Systematic review and meta-analysis of randomized controlled trials
Sourceopen_in_new

Goodman C, Keating G, Georgousopoulou E, Hespe C, Levett K. Probiotics for the prevention of antibiotic-associated diarrhoea: a systematic review and meta-analysis. BMJ Open. 2021;11(8):e043054. doi:10.1136/bmjopen-2020-043054. PMID:34385227.

Population: Adults receiving antibiotics across 42 randomized trials.

Dose protocol: Adult antibiotic-coadministration protocols with varied strains and dose ranges.

Key findings: Adult-only pooled analysis found lower AAD risk overall and stronger protection in higher-risk settings and some higher-dose protocols.

Notes: Useful as the cleaner adult modernization anchor for AAD rather than as a universal dose claim.

Paper content

This adult-only systematic review and meta-analysis updated the probiotic AAD literature with 42 randomized trials involving 11,305 participants. The pooled estimate suggested a 37% relative reduction in antibiotic-associated diarrhea risk (RR 0.63, 95% CI 0.54-0.73), with moderate GRADE certainty.

The review also found that higher-dose protocols and some Lactobacillus- or Bifidobacterium-dominant interventions appeared more effective than lower-dose or less specific approaches, while low-baseline-risk settings showed little clear benefit. It is useful because it modernizes the adult-only signal and keeps the message appropriately narrow: probiotic benefit depends on baseline risk, dose, and strain selection rather than the label alone.

probiotic-SRC-003Systematic review and meta-analysis
Sourceopen_in_new

Wanyama H, Akhtar TS, Abbas S. Probiotic use reduces the incidence of antibiotic-associated diarrhea among adult patients: a meta-analysis. Prz Gastroenterol. 2025;20(1):5-16. doi:10.5114/pg.2025.148486. PMID:40191517.

Population: Adults receiving antibiotics in randomized controlled trials of probiotic coadministration.

Dose protocol: Adult antibiotic-coadministration protocols with varied strains and dosing schedules.

Key findings: Updated adult-focused meta-analysis supported lower antibiotic-associated diarrhea risk with probiotic coadministration.

Notes: Strengthens the evidence while keeping the product-specific language tight.

Paper content

Updated adult-focused meta-analysis supported reduced antibiotic-associated diarrhea risk with probiotic coadministration, while reinforcing that benefits are protocol- and strain-specific rather than universal across all products.

probiotic-SRC-004Multicenter, randomized, double-blind, placebo-controlled, dose-ranging trial
Sourceopen_in_new

Whorwell PJ, Altringer L, Morel J, et al. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol. 2006;101(7):1581-1590.

Population: Women meeting Rome II criteria for IBS recruited from 20 primary care centers in the United Kingdom (n=362)

Dose protocol: Bifidobacterium longum 35624 at 1x10^8 CFU daily for 4 weeks in women with IBS.

Key findings: The 1x10^8 CFU dose improved abdominal pain, bloating, bowel dysfunction, and gas, while lower and higher doses did not separate from placebo.

Notes: Important because it demonstrates that IBS benefit is strain-specific and not simply better at the highest CFU count.

Paper content

Landmark dose-ranging RCT establishing that B. infantis 35624 (now B. longum subsp. longum 35624) at 1x10^8 CFU daily significantly reduces abdominal pain, bloating, bowel dysfunction, incomplete evacuation, straining, and gas in women with IBS compared with placebo. The study is notable for demonstrating a clear dose-response relationship where only the middle dose (1x10^8 CFU) was effective, while both lower (1x10^6) and higher (1x10^10) doses failed to separate from placebo. This non-linear dose-response has been attributed to potential immunological overstimulation at the highest dose and insufficient colonization at the lowest dose. The trial recruited across all IBS subtypes and used rigorous daily symptom capture. It remains one of the most frequently cited strain-specific probiotic trials in the IBS literature.

probiotic-SRC-005Systematic review and meta-analysis with trial sequential analysis
Sourceopen_in_new

Tang ASP, Quek J, Sulaimi F, Sim B, Kai TOS, Soon EY, Goh CN, Hsu JLJ, Lee CKL, Chong SKS, Sule AA, Ling RR, Siah KTH, Ng QX. Probiotics for Irritable Bowel Syndrome: An Updated Systematic Review and Meta-Analysis With Trial Sequential Analysis. J Gastroenterol Hepatol. 2026 Mar 12. doi:10.1111/jgh.70322. PMID:41820241.

Population: Adults with irritable bowel syndrome enrolled in 40 randomized placebo-controlled probiotic trials.

Dose protocol: Forty placebo-controlled adult IBS trials using heterogeneous oral probiotic strains and formulations.

Key findings: Pooled evidence showed lower IBS Symptom Severity Scores overall, but not a clear quality-of-life gain, and trial-sequential analysis still judged the evidence base underpowered.

Notes: Use to keep IBS guidance current while preserving uncertainty and heterogeneity.

Paper content

Updated pooled evidence suggests probiotics can reduce IBS symptom severity, but the review explicitly found that the information size remains insufficient and the certainty of evidence stays low because of inconsistency across strains and trials.

probiotic-SRC-006Randomized, double-blind, placebo-controlled trial
Sourceopen_in_new

Gupta V, Nag D, Garg P, et al. Effectiveness of Prophylactic Oral and/or Vaginal Probiotic Supplementation in the Prevention of Recurrent Urinary Tract Infections: A Randomized, Double-Blind, Placebo-Controlled Trial. Clin Infect Dis. 2024;78(5):1154-1164. doi:10.1093/cid/ciad766. PMID:38084984.

Population: Premenopausal women with recurrent urinary tract infections.

Dose protocol: Four-month oral and/or vaginal probiotic prophylaxis in premenopausal women with recurrent UTIs.

Key findings: Vaginal probiotic and combined oral-plus-vaginal protocols reduced recurrent symptomatic UTI burden and delayed first recurrence versus placebo.

Notes: Useful for urinary-health framing, but the route specificity means it should not be generalized to all oral probiotics.

Paper content

This randomized trial is useful because it moves probiotic urinary-health claims beyond vague class language. In 174 premenopausal women with recurrent UTIs, vaginal lactobacillus protocols, either alone or combined with oral probiotics, lowered recurrence burden and prolonged time to first symptomatic infection compared with placebo. Oral probiotics alone were less convincing. The study supports probiotic use in a narrow recurrent-UTI prevention context, but it does not justify broad claims for all probiotic products or for non-vaginal formulations in other populations.

probiotic-SRC-007Randomized controlled trial
Sourceopen_in_new

Shida K, et al. Daily intake of fermented milk with Lactobacillus casei strain Shirota reduces the incidence and duration of upper respiratory tract infections in healthy middle-aged office workers. Eur J Nutr. 2017;56(1):45-53. doi:10.1007/s00394-015-1056-1. PMID:26419583

Population: 96 healthy male office workers, winter season

Dose protocol: Lactobacillus casei Shirota fermented milk at 1x10^11 CFU daily for 12 weeks in healthy middle-aged male office workers.

Key findings: URTI incidence, URTI-free survival, and symptom-duration measures favored the probiotic fermented milk protocol.

Notes: Positive respiratory-symptom signal in one working-adult cohort.

Paper content

URTI incidence and duration improved versus control

probiotic-SRC-008Randomized, double-blind, placebo-controlled trial
Sourceopen_in_new

Gleeson M, et al. Effects of Lactobacillus casei Shirota ingestion on common cold infection and herpes virus antibodies in endurance athletes: a placebo-controlled, randomized trial. Eur J Appl Physiol. 2016;116(8):1555-1563. doi:10.1007/s00421-016-3415-x. PMID:27294502

Population: 243 university endurance athletes/games players

Dose protocol: Lactobacillus casei Shirota fermented milk twice daily for 20 weeks in endurance athletes.

Key findings: The athlete trial did not reduce upper-respiratory symptom incidence, duration, or severity despite some favorable herpes-virus antibody shifts.

Notes: Include to prevent overgeneralizing the more positive respiratory-infection trial.

Paper content

No URS clinical benefit; antibody titers improved in seropositive subgroup

probiotic-SRC-009Retrospective case series.
Sourceopen_in_new

Poncelet A, et al. Saccharomyces cerevisiae fungemia: Risk factors, outcome and links with S. boulardii-containing probiotic administration. Infect Dis Now. 2021;51(3):293-295. doi:10.1016/j.idnow.2020.12.003. PMID:33934809.

Population: 10 fungemia cases in a hospital setting.

Dose protocol: Hospital case series of Saccharomyces fungemia with and without documented probiotic exposure.

Key findings: Rare but serious Saccharomyces fungemia occurred in high-risk inpatients, including several with documented S. boulardii exposure.

Notes: Supports the live-organism safety cautions for central lines, critical illness, and immunocompromise.

Paper content

Rare but serious safety signal in high-risk hosts.

Guides

Setup

Help